Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Syros Pharmaceuticals
(NQ:
SYRS
)
2.510
-0.020 (-0.79%)
Streaming Delayed Price
Updated: 3:20 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
Next >
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
September 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
August 27, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Syros Pharmaceuticals's Earnings Outlook
March 26, 2024
Via
Benzinga
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
August 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
August 20, 2024
From
The Schall Law Firm
Via
Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
August 13, 2024
Via
Benzinga
Exposures
Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
August 13, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
August 13, 2024
Via
Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...
Via
Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
August 13, 2024
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 13, 2024
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.
Via
InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
August 13, 2024
Via
Benzinga
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
August 12, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update
July 31, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 24, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
June 13, 2024
From
Syros Pharmaceuticals
Via
Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 14, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Participate in Upcoming Investor Conferences
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
May 07, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
April 09, 2024
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0.46% to 38,713.72 while the NASDAQ fell 0.24% to 16,215.32. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 09, 2024
Via
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 09, 2024
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Via
Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
April 09, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
April 02, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
March 27, 2024
SYRS stock results show that Syros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 27, 2024
From
Syros Pharmaceuticals
Via
Business Wire
Earnings Scheduled For March 27, 2024
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.